1
|
Wang LX, Chen Y, Dong ST, Ren FG, Zhang YF, Chang JM, Tan YH, Chen XH, Wang HW, Xu ZF. [Expression characteristics and clinical significance of CD109 in de novo acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2023; 44:770-774. [PMID: 38049323 PMCID: PMC10630576 DOI: 10.3760/cma.j.issn.0253-2727.2023.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Indexed: 12/06/2023]
Affiliation(s)
- L X Wang
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - Y Chen
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - S T Dong
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - F G Ren
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - Y F Zhang
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - J M Chang
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - Y H Tan
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - X H Chen
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - H W Wang
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| | - Z F Xu
- Department of Haematology, The Second Hospital of Shanxi Medical University, Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases, Taiyuan 030001, China
| |
Collapse
|
2
|
Iannelli F, Zotti AI, Roca MS, Grumetti L, Lombardi R, Moccia T, Vitagliano C, Milone MR, Ciardiello C, Bruzzese F, Leone A, Cavalcanti E, De Cecio R, Iachetta G, Valiante S, Ionna F, Caponigro F, Di Gennaro E, Budillon A. Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. Front Cell Dev Biol 2020; 8:732. [PMID: 33015030 PMCID: PMC7461984 DOI: 10.3389/fcell.2020.00732] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 07/15/2020] [Indexed: 12/12/2022] Open
Abstract
Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. The combination of cisplatin (CDDP) plus cetuximab (CX) is one of the standard first-line treatments in this disease. However, this therapeutic regimen is often associated with high toxicity and resistance, suggesting that new combinatorial strategies are needed to improve its therapeutic index. In our study, we evaluated the antitumor effects of valproic acid (VPA), a well-known antiepileptic agent with histone deacetylase inhibitory activity, in combination with CDDP/CX doublet in head and neck squamous cell carcinoma (HNSCC) models. We demonstrated, in HNSCC cell lines, but not in normal human fibroblasts, that simultaneous exposure to equitoxic doses of VPA plus CDDP/CX resulted in a clear synergistic antiproliferative and pro-apoptotic effects. The synergistic antitumor effect was confirmed in four different 3D-self-assembled spheroid models, suggesting the ability of the combined approach to affect also the cancer stem cells compartment. Mechanistically, VPA enhanced DNA damage in combination treatment by reducing the mRNA expression of ERCC Excision Repair 1, a critical player in DNA repair, and by increasing CDDP intracellular concentration via upregulation at transcriptional level of CDDP influx channel copper transporter 1 and downregulation of the ATPAse ATP7B involved in CDDP-export. Valproic acid also induced a dose-dependent downregulation of epidermal growth factor receptor (EGFR) expression and of MAPK and AKT downstream signaling pathways and prevent CDDP- and/or CX-induced EGFR nuclear translocation, a well-known mechanism of resistance to chemotherapy. Indeed, VPA impaired the transcription of genes induced by non-canonical activity of nuclear EGFR, such as cyclin D1 and thymidylate synthase. Finally, we confirmed the synergistic antitumor effect also in vivo in both heterotopic and orthotopic models, demonstrating that the combined treatment completely blocked HNSCC xenograft tumors growth in nude mice. Overall, the introduction of a safe and generic drug such as VPA into the conventional treatment for R/M HNSCC represents an innovative and feasible antitumor strategy that warrants further clinical evaluation. A phase II clinical trial exploring the combination of VPA and CDDP/CX in R/M HNSCC patients is currently ongoing in our institute.
Collapse
Affiliation(s)
- Federica Iannelli
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Andrea Ilaria Zotti
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Maria Serena Roca
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Laura Grumetti
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Rita Lombardi
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Tania Moccia
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Carlo Vitagliano
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Maria Rita Milone
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Chiara Ciardiello
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Francesca Bruzzese
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Alessandra Leone
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Ernesta Cavalcanti
- Laboratory Medicine Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Rossella De Cecio
- Pathology Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | | | | | - Franco Ionna
- Maxillo-facial & ENT Surgery Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Francesco Caponigro
- Head and Neck Medical Oncology Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Elena Di Gennaro
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - Alfredo Budillon
- Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| |
Collapse
|
3
|
Matic N, Ressner M, Wiechec E, Roberg K. In vitro measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT. Oncol Lett 2019; 18:5155-5162. [PMID: 31620196 PMCID: PMC6788167 DOI: 10.3892/ol.2019.10916] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Accepted: 08/06/2019] [Indexed: 11/25/2022] Open
Abstract
The standard treatment for head and neck squamous cell carcinoma (HNSCC) is radiotherapy, often in combination with chemotherapy or surgery. However, a novel monoclonal antibody, cetuximab (Erbitux®), has also been approved for patient therapy. The aim of present study was to develop an in vitro method for the measurement of 18F-fluoro-2deoxy-D-glucose (FDG) to determine if cellular 18F-FDG uptake is associated with response to radiotherapy or cetuximab treatment. In the current study, HNSCC cell lines were treated with radiation or with cetuximab. Next, the uptake of 18F-FDG was measured using a gamma spectrometer (GS). Thereafter, uptake after radiation was measured first with GS and then compared with positron emission tomography (PET)/computed tomography (CT) imaging. Furthermore, the mRNA expression of glucose transporter 1 (GLUT1) was measured following cetuximab treatment via reverse transcription-quantitative PCR. A study protocol was developed to measure the cellular uptake of 18F-FDG via gamma-ray spectrometry and comparable results were obtained with those of clinical PET/CT. The results revealed a decrease in 18F-FDG after radiation and cetuximab treatment. The uptake of 18F-FDG following cetuximab treatment was significantly lower in the cetuximab-sensitive cell line UT-SCC-14 compared with the cetuximab-resistant cell lines UT-SCC-2 and UT-SCC-45. Furthermore, after treatment with cetuximab for 24 and 48 h, a significant increase in GLUT1 expression was detected in the sensitive cell line compared with the two resistant cell lines. In conclusion, a novel yet reliable method for the measurement of intracellular 18F-FDG via GS has been developed, and our results indicate that 18F-FDG uptake is associated with radiation and cetuximab response in HNSCC.
Collapse
Affiliation(s)
- Natasa Matic
- Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Östergötland SE-58185, Sweden.,Department of Otorhinolaryngology in Linköping, Anesthetics, Operations and Specialty Surgery Center, University Hospital, Linköping, Östergötland SE-58185, Sweden
| | - Marcus Ressner
- Center for Medical Image Science and Visualization, Linköping University, Linköping, Östergötland SE-58185, Sweden
| | - Emilia Wiechec
- Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Östergötland SE-58185, Sweden
| | - Karin Roberg
- Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Östergötland SE-58185, Sweden.,Department of Otorhinolaryngology in Linköping, Anesthetics, Operations and Specialty Surgery Center, University Hospital, Linköping, Östergötland SE-58185, Sweden
| |
Collapse
|
4
|
Eriksson P, Tal AA, Skallberg A, Brommesson C, Hu Z, Boyd RD, Olovsson W, Fairley N, Abrikosov IA, Zhang X, Uvdal K. Cerium oxide nanoparticles with antioxidant capabilities and gadolinium integration for MRI contrast enhancement. Sci Rep 2018; 8:6999. [PMID: 29725117 PMCID: PMC5934375 DOI: 10.1038/s41598-018-25390-z] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Accepted: 03/19/2018] [Indexed: 12/26/2022] Open
Abstract
The chelating gadolinium-complex is routinely used as magnetic resonance imaging (MRI) -contrast enhancer. However, several safety issues have recently been reported by FDA and PRAC. There is an urgent need for the next generation of safer MRI-contrast enhancers, with improved local contrast and targeting capabilities. Cerium oxide nanoparticles (CeNPs) are designed with fractions of up to 50% gadolinium to utilize the superior MRI-contrast properties of gadolinium. CeNPs are well-tolerated in vivo and have redox properties making them suitable for biomedical applications, for example scavenging purposes on the tissue- and cellular level and during tumor treatment to reduce in vivo inflammatory processes. Our near edge X-ray absorption fine structure (NEXAFS) studies show that implementation of gadolinium changes the initial co-existence of oxidation states Ce3+ and Ce4+ of cerium, thereby affecting the scavenging properties of the nanoparticles. Based on ab initio electronic structure calculations, we describe the most prominent spectral features for the respective oxidation states. The as-prepared gadolinium-implemented CeNPs are 3-5 nm in size, have r1-relaxivities between 7-13 mM-1 s-1 and show clear antioxidative properties, all of which means they are promising theranostic agents for use in future biomedical applications.
Collapse
Affiliation(s)
- Peter Eriksson
- Division of Molecular Surface Physics and Nanoscience, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden
| | - Alexey A Tal
- Division of Theoretical Physics, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden
- Materials Modeling and Development Laboratory, National University of Science and Technology "MISIS", 119049, Moscow, Russia
| | - Andreas Skallberg
- Division of Molecular Surface Physics and Nanoscience, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden
| | - Caroline Brommesson
- Division of Molecular Surface Physics and Nanoscience, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden.
| | - Zhangjun Hu
- Division of Molecular Surface Physics and Nanoscience, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden
| | - Robert D Boyd
- Plasma Coatings Physics, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden
| | - Weine Olovsson
- Division of Theoretical Physics, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden
| | - Neal Fairley
- Casa Software Ltd, Bay House, 5 Grosvenor Terrace, Teignmouth, TQ14 8NE, United Kingdom
| | - Igor A Abrikosov
- Division of Theoretical Physics, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden
- Materials Modeling and Development Laboratory, National University of Science and Technology "MISIS", 119049, Moscow, Russia
| | - Xuanjun Zhang
- Faculty of Health Sciences, University of Macau, Macau, SAR, China
| | - Kajsa Uvdal
- Division of Molecular Surface Physics and Nanoscience, Department of Physics, Chemistry and Biology (IFM), Linköping University, SE-581 83, Linköping, Sweden.
| |
Collapse
|
5
|
Qi R, Dong F, Liu Q, Murakumo Y, Liu J. CD109 and squamous cell carcinoma. J Transl Med 2018; 16:88. [PMID: 29625613 PMCID: PMC5889571 DOI: 10.1186/s12967-018-1461-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2017] [Accepted: 03/27/2018] [Indexed: 12/16/2022] Open
Abstract
Squamous cell carcinoma (SCC) is well-known for its high rate of metastasis with poor prognosis. CD109 is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. Recently, CD109 emerges as a potential biomarker and a therapeutic target for SCCs. Accumulating studies have reported that CD109 is highly expressed in human SCCs of multiple organs, and may contribute to the progression of SCCs. In this review, we summarized the findings on expression pattern of CD109 in SCCs, and discussed the molecular mechanisms underlying the roles of CD109 in pathogenesis of SCCs.
Collapse
Affiliation(s)
- Ruixia Qi
- Taishan Medical College, Tai'an, Shandong, China.,Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, 250014, Shandong, China
| | - Fengyun Dong
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, 250014, Shandong, China
| | - Qiang Liu
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, 250014, Shandong, China
| | - Yoshiki Murakumo
- Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan
| | - Ju Liu
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, 250014, Shandong, China.
| |
Collapse
|
6
|
Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells. Int J Mol Sci 2017; 18:ijms18050943. [PMID: 28468237 PMCID: PMC5454856 DOI: 10.3390/ijms18050943] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2017] [Revised: 04/19/2017] [Accepted: 04/24/2017] [Indexed: 01/01/2023] Open
Abstract
Despite advances in the head and neck squamous cell carcinoma (HNSCC) treatment modalities, drug resistance and cancer recurrence are often reported. Hypoxia signaling through hypoxia-inducible factor 1 (HIF-1) promotes angiogenesis and metastasis by inducing epithelial-mesenchymal-transition (EMT). The aim of this study was to evaluate the impact of hypoxia on response to therapy as well as EMT and expression of stem cell markers in HNSCC cells. Five HNSCC cell lines (UT-SCC-2, UT-SCC-14, LK0412, LK0827, and LK0923) were selected for this study. The treatment sensitivity for radiation, cisplatin, cetuximab, and dasatinib was assessed by crystal violet assay. Gene expression of EMT and cancer stem cell (CSC) markers as well as protein level of EGFR signaling molecules were analyzed by qPCR and western blotting, respectively. Unlike UT-SCC-14 and LK0827, the LK0412 cell line became significantly more sensitive to cetuximab in hypoxic conditions. This cetuximab sensitivity was efficiently reversed after suppression of HIF-1α with siRNA. Additionally, hypoxia-induced EMT and expression of stem cell markers in HNSCC cells was partially revoked by treatment with cetuximab or knockdown of HIF-1α. In summary, our study shows that hypoxia might have a positive influence on the anti-EGFR therapy effectiveness in HNSCC. However, due to heterogeneity of HNSCC lesions, targeting HIF-1α may not be sufficient to mediate such a response. Further studies identifying a trait of hypoxia-specific response to cetuximab in HNSCC are advisable.
Collapse
|